+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors



Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors



Biomedical Reports 5(2): 165-170



It has been indicated that proton pump inhibitor (PPI) use is associated with a loss of the anti-fracture efficacy of alendronate (AD). However, there are few prospective studies that have investigated the efficacy of AD on lumbar bone mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim of the present study was to investigate the efficacy of alfacalcidol (AC) and AD on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, active control study enrolled such osteoporotic patients (age, ≥50 years). The patients were randomly assigned to receive AC (1 µg/day) or AD (35 mg/week) and were followed up for one year. Patient profiles were maintained, and lumbar BMD, bone-specific alkaline-phosphatase (BAP) and collagen type-I cross-linked N-telopeptide (NTX), upper gastrointestinal endoscopy results, and the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) were evaluated. Percentage changes in lumbar BMD, NTX, BAP, and change in FSSG score from baseline to the end of one year of treatment were investigated. Sixteen patients were eligible for analysis (eight assigned to receive AC, eight assigned to receive AD). The percentage change in lumbar BMD from baseline to the end of treatment was -0.4±4.0% for the AC group vs. 6.8±6.3% for the AD group (P=0.015). No significant percentage change of BAP and NTX between the two groups was observed. Subsequent to one year of treatment, the FSSG score did not change from the baseline values for either study group, and no new bone fractures or esophagitis were observed in either group of patients. The findings demonstrated that in osteoporotic patients using concomitant PPIs, there was a greater increase in lumbar BMD after one year of treatment with AD compared with AC. However, the number of study subjects was small; thus, further, large prospective studies are required to determine the effect of AD in osteoporotic patients using concomitant PPIs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057740143

Download citation: RISBibTeXText

PMID: 27446535

DOI: 10.3892/br.2016.710


Related references

Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women. Journal of Medical Investigation 54(1-2): 35-40, 2007

Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplantation Proceedings 40(1): 160-166, 2008

A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. Journal of Bone and Joint Surgery. American Volume 93(13): 1203-1209, 2011

Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid. Modern Rheumatology 24(4): 671-676, 2014

Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging Clinical and Experimental Research 17(2): 157-163, 2005

The impact of alendronate on bone mineral density of osteoporotic patients. Acta Medica Iranica 51(12): 855-860, 2013

Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. Journal of Bone and Mineral Metabolism 28(2): 202-208, 2010

Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients. Zhonghua Nei Ke Za Zhi 45(7): 565-568, 2006

Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. Journal of Musculoskeletal and Neuronal Interactions 11(1): 34-45, 2011

Effect of pamidronate and alendronate on bone mineral density in osteoporotic patients A control matched Study. Journal of Bone & Mineral Research 17(Suppl 1): S473, 2002

Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. Journal of Rheumatology 34(5): 1051-1057, 2007

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Medical Journal 50(4): 474-481, 2009

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture. Therapeutics and Clinical Risk Management 7: 257-264, 2011

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2016

Treatment of renal transplant recipients with low bone mineral density: A randomized prospective trial of alendronate, alfacalcidol,. 2008